Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Radio Nuclide Therapy: From Molecular to Cure
share announcement

Radio Nuclide Therapy: From Molecular to Cure

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 1723

Special Issue Editor

Dr. Carlo Aprile

E-Mail Website
Guest Editor
Nuclear Medicine Unit, IRCCS Fondazione Policlinico San Matteo, I-27100 Pavia, Italy
Interests: molecular imaging; radiopharmacology; bone metastases therapy; amyloidosis; intraoperative detection
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

After the introduction of radioiodine therapy for thyrotoxicosis and differentiated thyroid cancer in the middle of the last century, radionuclide therapy (RNT) underwent an enormous development exploring innovative ways.

Despite this, RNT faces many challenges and limitations:

  • A molecular vector with high affinity and specificity for the tumor target;
  • A nuclide, preferable a true theranostic, with the emission and effective half-life fitting with uptake rate and residence in the target;
  • The chelator and cages;
  • Nanogenerators;
  • Tumor cells kinetics and metabolism;
  • Cell radiobiology;
  • Combined use with chemotherapeutics, biological drugs and EBRT, beta and alpha sequence.

We cordially invite authors in the field to submit original research or review articles pertaining to this important and fast-progressing field of biomedicine.

Dr. Carlo Aprile
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • alpha emission
  • beta emission
  • radiobiology
  • cancer therapy
  • radiopharmaceutical
  • internal radiotherapy
  • radionuclides
  • theranostic

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 2912 KiB  
Article
Exploring the Potential of Zirconium-89 in Diagnostic Radiopharmaceutical Applications: An Analytical Investigation
by Ahmed M. A. Mostafa, Hesham M. H. Zakaly, Shams A. M. Issa, Mohamed A. M. Uosif, Ziyad A. Alrowaili and Michael V. Zhukovsky
Biomedicines 2023, 11(4), 1173; https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines11041173 - 13 Apr 2023
Cited by 1 | Viewed by 1246
Abstract
This study highlights the use of 89Zr-oxalate in diagnostic applications with the help of WinAct and IDAC2.1 software. It presents the biodistribution of the drug in various organs and tissues, including bone, blood, muscle, liver, lung, spleen, kidneys, inflammations, and tumors, and [...] Read more.
This study highlights the use of 89Zr-oxalate in diagnostic applications with the help of WinAct and IDAC2.1 software. It presents the biodistribution of the drug in various organs and tissues, including bone, blood, muscle, liver, lung, spleen, kidneys, inflammations, and tumors, and analyzes the maximum amount of nuclear transformation per Bq intake for each organ. The retention time of the maximum nuclear transformation and the absorbed doses of the drug in various organs and tissues are also examined. Data from clinical and laboratory studies on radiopharmaceuticals are used to estimate the coefficients of transition. The accumulation and excretion of the radiopharmaceutical in the organs is assumed to follow an exponential law. The coefficients of transition from the organs to the blood and vice versa are estimated using a combination of statistical programs and digitized data from the literature. WinAct and IDAC 2.1 software are used to calculate the distribution of the radiopharmaceutical in the human body and to estimate the absorbed doses in organs and tissues. The results of this study can provide valuable information for the biokinetic modeling of wide-spectrum diagnostic radiopharmaceuticals. The results show that 89Zr-oxalate has a high affinity for bones and a relatively low impact on healthy organs, making it helpful in targeting bone metastases. This study provides valuable information for further research on the development of this drug for potential clinical applications. Full article
(This article belongs to the Special Issue Radio Nuclide Therapy: From Molecular to Cure)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop